HeraMED (ASX:HMD) completes HeraBEAT trial with “excellent” results

July 20, 2022

Pregnancy technology company HeraMED (HMD) has completed the HeraBEAT clinical trial with Israel’s Sheba Medical Center which achieved “excellent” results.

The study was led by Director of the Sheba Women’s Health Innovation Center and OBGYN Beyond Dr Avi Tsur to determine the feasibility of extending remote pregnancy capabilities.

A total of 10 patients were recruited in the study and went through an observation telemedicine visit using HeraBEAT.

The trial measured the patients’ first in-person visit compared to the telemedicine encounter.

Notably, there was a 60 per cent reduction in time for the telemedicine visit, potentially saving over 2.5 hours for patients and the staff.

The study concluded that remote assessment is feasible, saves time and results in higher patient satisfaction levels. It also confirmed clinical, economic, social and logistical advantages.

HeraBEAT is a smartphone-based foetal heartbeat monitor that is designed for home use, enabling expecting mothers to monitor their foetus’ heartbeat anytime, anywhere.

The data can then be stored and shared with medical professionals which enables parents to rest while their foetus is receiving medical attention.

“We are excited by the results coming out of this Sheba study, which indicate, once again, that our fetal and maternal heart rate monitor HeraBEAT is helping break down the technology barriers previously precluding the delivery of effective remote telemedicine monitoring for expectant mothers,” CEO and Co-Founder David Groberman commented.

“An added bonus in the current environment is that the remote monitoring functionality provided by HeraBEAT also helps limit the spread of the COVID-19 pandemic amongst expectant mothers.”

Published July 19, 2022, The Market Herald